Nothing obviously great in yesterday's earnings call. Their expected $60 MM milestone payment from Mylan for M834, the Orencia biosimilar, in the second half of 2016 is a good thing though.
“It is possible to be a normal decent person and yet to be fully alive.” - George Orwell